Compare AMBQ & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | LXRX |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 703.3M |
| IPO Year | N/A | 2000 |
| Metric | AMBQ | LXRX |
|---|---|---|
| Price | $81.66 | $2.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $42.20 | $4.15 |
| AVG Volume (30 Days) | 735.5K | ★ 4.5M |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $22.12 | $1.00 |
| 52 Week High | $91.61 | $2.68 |
| Indicator | AMBQ | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 49.25 |
| Support Level | $73.59 | $2.04 |
| Resistance Level | $88.50 | $2.61 |
| Average True Range (ATR) | 6.24 | 0.15 |
| MACD | -0.87 | -0.03 |
| Stochastic Oscillator | 47.07 | 21.09 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.